AURKA inhibitors: Right in time

Pediatric Blood and Cancer

Volumn 55, Issue 1, 2010, Pages 3-4

  Kovar, Heinrich ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

4 [[9 CHLORO 7 (2,6 DIFLUOROPHENYL) 5H PYRIMIDO[5,4 D][2]BENZAZEPIN 2 YL]AMINO]BENZOIC ACID; ALKALOID DERIVATIVE; AURORA KINASE INHIBITOR; BENZODIAZEPINE; MLN 8237; UNCLASSIFIED DRUG;

ACUTE LYMPHOBLASTIC LEUKEMIA; ANEUPLOIDY; BREAST CANCER; CANCER CLASSIFICATION; CANCER RELAPSE; CELL DIVISION; CHILDHOOD CANCER; CHROMOSOME SEGREGATION; CLINICAL FEATURE; CLINICAL TRIAL; CYTOKINESIS; DRUG BIOAVAILABILITY; DRUG TOLERABILITY; EVENT FREE SURVIVAL; GENE EXPRESSION; GENE NUMBER; GENE OVEREXPRESSION; HUMAN; IC 50; LIPOSARCOMA; MITOSIS; MUSCLE SPINDLE; NEUROBLASTOMA; NONHUMAN; NOTE; PRIORITY JOURNAL; SOLID TUMOR; TREATMENT RESPONSE; TUMOR GROWTH; VINCA;

ANIMALS; ANTINEOPLASTIC AGENTS; AZEPINES; CELL PROLIFERATION; DRUG SCREENING ASSAYS, ANTITUMOR; HUMANS; MICE; NEOPLASMS; PROTEIN KINASE INHIBITORS; PROTEIN-SERINE-THREONINE KINASES; PYRIMIDINES;

EID: 77953278275     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.22548     Document Type: Note

References (10)

1. Gautschi O, Heighway J, Mack PC, et al. Aurora kinases as anticancer drug targets. Clin Cancer Res 2008;14:1639-1648. (Pubitemid 351471713)
2. Cervantes-Ruiperez A, Elez ME, Roselló S, et al. Phase I pharmacokinetic (PK) and pharmacodynamic (PD) study of MLN8237, a novel selective aurora A kinase (AAK) inhibitor, in patients (pts) with advanced solid tumors. J Clin Oncol 2009;27:15s (Suppl; Abstr 2565).
3. Maris JM, Morton CL, Gorlick R, et al. Initial testing of the aurora kinase a inhibitor MLN8237 by the Pediatric Preclinical Testing Program (PPTP). Pediatr Blood Cancer 2010; Jan 27. [Epub ahead of print].
4. Vader G, Lens SM. The Aurora kinase family in cell division and cancer. Biochim Biophys Acta 2008;1786:60-72.
5. Hirota T, Kunitoku N, Sasayama T, et al. Aurora-A and an interacting activator, the LIM protein Ajuba, are required for mitotic commitment in human cells. Cell 2003;114:585-598. (Pubitemid 37159255)
6. Bibby RA, Tang C, Faisal A, et al. A cancer-associated aurora A mutant is mislocalized and misregulated due to loss of interaction with TPX2. J Biol Chem 2009;284:33177-33184.
7. Bird AW, Hyman AA. Building a spindle of the correct length in human cells requires the interaction between TPX2 and Aurora A. J Cell Biol 2008;182:289-300.
8. Mao JH, Wu D, Perez-Losada J, et al. Crosstalk between Aurora-A and p53: frequent deletion or downregulation of Aurora-A in tumors from p53 null mice. Cancer Cell 2007;11:161-173. (Pubitemid 46209850)
9. Ewart-Toland A, Briassouli P, de Koning JP, et al. Identification of Stk6/STK15 as a candidate low-penetrance tumor-susceptibility gene in mouse and human. Nat Genet 2003;34:403-412. (Pubitemid 36935333)
10. Zhang M, Huck J, Hyer M, et al. Effect of Aurora A kinase inhibitor MLN8237 combined with rituximab on antitumor activity in preclinical B-cell non-Hodgkin's lymphoma models. J Clin Oncol 2009;27:15s (Suppl; Abstr 8553).